Background: Population studies suggest that high body mass index (BMI) correlates with a reduced risk for death from lung cancer. The aim of our study was to evaluate definitively the influence of BMI on long-term overall survival (OS) in surgical patients with NSCLC.
Results: On univariate analysis, significant predictors of improved survival were higher BMI, pathologic tumor stage (stage I versus stage II, III, or IV), type of surgical procedure (lobectomy/pneumonectomy versus wedge resection/ segmentectomy), younger age, female sex, and adenocarcinoma histologic subtype (versus squamous) (all p < 0.05). 
Conclusions:
In this large, retrospective, single-center series, after control for disease stage and other variables,
Introduction
Body mass index (BMI), a ratio of weight relative to height measured in kilograms per square meters of height has been correlated with various metabolic and cardiovascular diseases and cancer. 1 Although there are other measures of body composition, BMI has become a *Corresponding author.
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common tool in the estimation of health risk. Specifically, severe obesity, defined as a BMI of 40 kg/m 2 or higher, has been associated with death rates from all cancers combined to be 52% higher for men and 62% higher for women than those for men and women of healthy weight. 1 However, the relationship between high BMI and high risk for mortality due to cancer is not consistent among different types of cancer. Although obesity is associated with higher rates of mortality due to gastrointestinal malignancies (esophagus, stomach, gallbladder, pancreas, and colon), prostate cancer, and breast cancer, obese individuals are less likely to die of renal cell cancer, diffuse large B-cell lymphoma, and lung cancer. 1 1 Whether this phenomenon represents simple protection from cancer-related cachexia or whether other molecular or metabolic mechanisms are engaged is yet to be determined.
In surgically resected lung cancer, two previous studies have focused on the analysis of short-term/ perioperative outcomes in patients with a high BMI. In one study using the National Surgical Quality Improvement Program database, high BMI did not negatively influence 30-day perioperative mortality, hospital length of stay, or perioperative complications after pulmonary resection.
2 A similar study of 1369 patients treated surgically for lung cancer at a single institution also demonstrated similar perioperative outcomes despite a varied range of BMI values. 3 Long-term oncologic survival of patients with lung cancer based on their BMI has been studied in patients with advanced lung cancer. 4 In a study incorporating data from three cooperative group trials of first-line chemotherapy in metastatic NSCLC, obese patients were found to have longer overall survival (OS) than healthy or overweight patients in multivariate Cox models (hazard ratio [HR] ¼ 0.86, p ¼ 0.04, 95% CI: 0.75-0.99). 4 One other study of 337 patients focused on long-term outcomes based on BMI in surgically resected lung cancer and found high BMI to have a protective effect. 5 Recently, a meta-analysis of 25 surgical observational studies concluded that the "obesity paradox" has a potential to exist in lung cancer surgery; this statement was based on the results, which demonstrated that obesity had a favorable effect on both in-hospital outcomes and longterm survival of surgical patients with lung cancer.
Our study aimed to contribute to prior work on this topic by evaluating the impact of BMI on OS in a large cohort of patients with surgically resected NSCLC.
Methods
After the waiver of consent and approval for this retrospective study from the M. D. Anderson Cancer Center Institutional Review Board had been obtained, a prospectively maintained thoracic surgical department database was queried for patients who underwent surgical resection for NSCLC between January 2000 and December 2013. Inclusion criteria consisted of patients age 18 through 85 years who underwent wedge resection, segmentectomy, lobectomy, or pneumonectomy. Neoadjuvant or adjuvant chemotherapy or radiation therapy was allowed for inclusion in the study. Only patients with a non-small cell carcinoma histologic subtype (adenocarcinoma, squamous cell carcinoma, large cell carcinoma, or NSCLC not otherwise specified) were included in the study. Considering the goal of studying long-term OS outcomes, we excluded patients whose long-term survival could be influenced by perioperative events, such as death within 90 days of operation, intraoperative or postoperative blood transfusion, postoperative stay in the intensive care unit, or postoperative pneumonia. We also excluded patients with missing information about pathologic stage or BMI. The initial search identified 3768 patients from 1999-2013 in the database. After exclusions and limitation of the series to the years 2000-2013, the final study population consisted of 1935 patients (see the CONSORT diagram in Fig. 1 ). The reasons for the aforementioned exclusion criteria were to minimize confounding variables and to study the effect of BMI in a homogenous cohort of patients (i.e., patients who underwent uncomplicated surgical therapy for lung cancer).
Collected study variables included patients' demographic characteristics, BMI, type of operative procedure, type of neoadjuvant and/or adjuvant therapy, tumor histologic subtype, pathologic stage, age, sex, smoking history, and time from surgery to death or last follow-up.
Statistics
The primary study outcome was OS of the entire patient population and the patient subgroups based on BMI. Four groups of patients based on their BMI were identified: BMI less than 25 kg/m 2 (healthy), BMI of 25 to 30 kg/m 2 (overweight), BMI higher than 30 to 35 kg/m 2 (obese), and BMI higher than 35 kg/m 2 (morbidly obese). In the group with a healthy BMI less than 25 kg/m 2 , we also included 20 patients with a BMI less than 19 kg/m 2 (underweight). In a separate preliminary analysis, these patients had outcomes similar to those of the group with a BMI of 20 to 25 kg/m 2 and were therefore included in the healthy BMI group. We initially performed univariate analysis to identify variables associated with survival; a p value less than 0.05 was considered statistically significant. Variables with a p value less than 0.25 on univariate analysis were then tested in the multivariate Cox regression model. Survival analysis was performed by the Kaplan-Meier method. Survival was calculated from the time of surgery to death or last follow-up. Patients who remained alive were censored at the time of last follow-up.
After we detected the difference in OS between the groups based on the BMI, we performed propensity score matching to learn whether the difference in survival between the groups persisted. The final KaplanMeier analyses compared survival of patients with a BMI less than 25 kg/m 2 (healthy), a BMI of 25 to 30 kg/m 2 , a BMI of 30 to 35 kg/m 2 , and a BMI higher than 35 kg/m 2 matched for variables significant on the multivariate analysis. Statistical analyses were performed with SPSS software, version 23 (IBM Corp., Armonk, NY).
For an additional analysis of lung cancer survival on the basis of genes associated with obesity, we explored the obesity-related genes in The Cancer Genome Atlas (TCGA). Genetic and clinical data for lung adenocarcinoma and squamous cell carcinoma were downloaded from the TCGA database (http://www.cbioportal.org/). This was a separate data set unrelated to the clinical data or tumor tissue for 1935 patients in this study.
Results
Demographic variables of the study population of 1935 patients are presented in (Table 2 ). When BMI was tested as a continuous variable, a significant (p < 0.01) association was observed with survival with OR (0.98), implying that for every unit of increase in BMI, there was a 2% improvement in OS (see Table 2 ). In a multivariate Cox regression model, increasing BMI remained as a significant independent predictor of survival (p ¼ 0.03, OR ¼ 0.977) ( Table 3 ). Other factors associated with survival in the multivariate model included age, male sex, wedge resection, segmentectomy, and smoking (see Table 3 ).
The initial Kaplan-Meier analyses demonstrated significant differences in survival in patients with a BMI less than 25 kg/m 2 compared with in those with a BMI of 30 kg/m 2 or higher and those with a BMI of 35 kg/m 2 or higher. On the basis of these findings, we performed a propensity score matching analysis of patients with a BMI less than 25 kg/m 2 and patients with a BMI of 30 kg/m 2 or higher and a BMI of 35 kg/m 2 or higher (Fig. 2) . A total of 464 patients in each group were matched on the basis of the following variables: age, sex, type of surgical procedure, histologic subtype, pathologic stage, and smoking. Kaplan-Meier analyses of propensity score-matched patients demonstrated significantly better OS in patients with a BMI of 30 kg/m 2 or higher than in patients with a BMI less than 25 kg/m 2 and even better OS in patients with a BMI of 35 kg/m 2 or higher (p ¼ 0.003) (see Fig. 2 ).
For the exploratory analysis of expressed genes associated with obesity and lung cancer survival, we further analyzed the association between obesity genes (leptin gene [ 9 and lung cancer survival from a separate TCGA data set. The TCGA is an independent and centralized database with genomic and genetic profiles of various cancer patients, including lung cancer. The only significant difference in OS we detected on exploratory KaplanMeier analyses in this TCGA cohort was in the group with high expression of uncoupling protein 2 (UCP2).
Discussion
Our retrospective analysis of 1935 patients with lung cancer from a single center demonstrates that patients with a BMI of 30 kg/m 2 or higher, who are classified as obese, experience OS superior to that of patients with a BMI considered healthy (<25 kg/m 2 ). These results are consistent with the previous reports evaluating the role of BMI in OS in advanced NSCLC 4 as well as in surgically resected lung cancer. 5, 6 In the study by Dahlberg et al., 4 the authors combined data from three phase III clinical trials of first-line systemic chemotherapy for stage IIIB, stage IV, or recurrent NSCLC. They analyzed OS for 2585 patients on the basis of their BMI and found that within the first 16 months patients with a BMI in the obese range experienced survival superior to that of nonobese patients (HR ¼ 0.86). This trend, however, was reversed at 16 months (HR ¼ 1.54). 4 In our study, the observation of improved outcome in the high-BMI group persisted throughout the study follow-up period (mean follow-up time 45.16 months). Although the authors did not provide an explanation for the early survival benefit in obese patients, they postulated that the synergy between perixome proliferator-activated receptor ligands such as fatty acids, antidiabetic drugs, and platinum chemotherapy could provide a biological basis for the reasoning behind their observation. 4 A group from Liverpool (United Kingdom) reported on outcomes of 337 propensity-matched patients with a BMI higher than 30 kg/m 2 and a BMI less than 30 kg/m 2 who underwent surgical resection for lung cancer. As in our study, the authors observed significantly improved OS in patients with a BMI of 30 kg/m 2 or higher as compared with in patients with a BMI less than 30 kg/m 2 .
5
Recently, Li et al. conducted a review and metaanalysis of the prognostic role of BMI for patients undergoing a lung cancer operation. 6 In their review they identified 25 observational studies with 78,143 patients who were included in the analysis. With respect to longterm survival, obesity was associated with a favorable long-term prognosis with OR ¼ 0.78 (95% CI: 0.63-0.98, p ¼ 0.031). The authors concluded that the obesity paradox does have the potential to exist in the group of patients undergoing a lung cancer operation and offered some interesting hypotheses for possible mechanisms underlying the paradox. 6 They suggested that obesity may be more prevalent in younger patients, who are more likely to withstand surgical trauma and may recover better. Another hypothesis suggests that obese patients have more medical problems and therefore seek medical attention sooner and are thus medically managed better than patients with a healthy BMI, who may avoid medical care. They also postulate that obese patients have better nutritional status, which leads to their better longevity after surgical lung cancer therapy. Lastly, they suggest that it is the undernourished patients who do poorly rather than the obese patients who do better. 6 Although all these hypotheses may have some merit, they remain speculative.
Another study combining large data sets of patients with lung cancer focused on the relationship between survival and obesity or weight loss in 76,086 patients, of whom 14,751 presented with obesity and/or weight loss. 7 In this large population study, patients who were obese at the time of lung cancer diagnosis demonstrated longer median survival relative to nonobese patients (13.0 versus 8.6 months, p < 0.001). This observation was significant across all stages and histologic subtypes. The authors hypothesized that the protective effect of obesity in lung cancer survival might relate to greater physiologic reserve and prolongation of life might be due to avoidance of cancer-related cachexia. 6 Although death from cancer cachexia may sound logical, in reality there is no clear evidence that cancer-related cachexia is the major mode of mortality in patients who had lung cancer. Conversely, a study by Ross et al. found that weight loss as a symptom of lung cancer predicted chemotherapy treatment toxicity and was associated with shortened survival. 8 Patients who experienced weight loss were less likely to finish three cycles of chemotherapy and experienced development of anemia significantly more often. 8 A small number of studies have investigated possible cellular mechanisms for lung cancer-related cachexia. A small study by Murton et al. found patients with lung cancer cachexia who had high mRNA levels of interleukin-6 and a low intramyocellular lipid content in slow twitch fibers. 9 Fukawa et al. studied fatty acid oxidation and muscle atrophy in cancer-related cachexia in vitro and in vivo. 10 They found that cachectic cancer cells secrete inflammatory factors and rapidly induce excessive fatty acid oxidation in myotubules, which causes oxidative stress and muscle atrophy. 10 Could the protective survival effect of higher BMI be due to larger fatty acid storage? This hypothesis would require further exploration.
With the available data from the TCGA database, we sought to explore the genetic connection behind the correlation of high BMI and better lung cancer survival. Most genetic abnormalities in lung cancer tissue are somatic change, whereas the genetic predisposition to obesity is germline, which makes the association analysis of obesity and lung cancer more complex. In addition, the genetic abnormalities related to lung cancer survival are usually studied in cancer tissue, whereas those related to obesity are usually studied in other tissues.
We examined the association between genes associated with obesity and survival in the TCGA data set. 11 The chief expressed genes of interest from the TCGA were LEP, LEPR, PCSK1, POMC, MC4R, BMIQ1, BMIQ2, BMIQ3, UCP2, BMIQ5, BMIQ6, INSIG2, FTO, TMEM18, GNPDA2, NEGR1, BDNF, KCTD15, SH2B1, MTCH2, and NPC1.
11 The TCGA data set showed significantly better OS in patients with high UCP2 expression. UCP2 belongs to the mitochondrial uncoupling protein family and was reported to suppress mitochondrial production of reactive oxygen species. However, recent studies have shown that UCP2 promotes fatty acid oxidation and limits glycolysis-derived pyruvate utilization. As a consequence, upregulation of UCP2 inhibits proliferation of cancer cells. 12, 13 We recognize that our study has limitations, mainly related to its retrospective nature. Considering the fact that our cohort consists mainly of surgical patients, selection bias may have played a role in our results. However, other confounding variables could not be controlled and might have influenced our results. For example, patients' metabolic profiles (lipid level, glucose level, and all other metabolic parameters that were measured in the clinic) were not well studied, which could potentially provide a hypothesis for future study. Another limitation of our study is the lack of valid information on adjuvant chemotherapy (only 11.2% patients had a valid record of adjuvant chemotherapy), which limits our ability to analyze how adjuvant therapy affects patients' survival. This should be addressed in future study.
Our results independently confirmed the studies by Attaran et al. 5 and Li et al. 6 and strengthened the argument that the obesity paradox in patients with surgically resected lung cancer is a consistent clinical feature of human lung cancer. In our study, we elected to exclude patients with perioperative mortality or major complications to avoid confounding factors known to influence long-term survival. We also excluded patients with perioperative blood transfusions because the meta-analysis by Luan et al. demonstrated worse oncologic outcomes in patients with lung cancer after perioperative blood transfusion.
14 In addition to the factors discussed, we also compared the follow-up time in each BMI group. In our study, the median follow-up time was 45.16 months and there was no statistic significant difference between all BMI groups (p ¼ 0.5).
Interestingly, we found that BMI is an independent variable in prediction of survival of patients with lung cancer after surgery. We also analyzed recent or former smokers in our cohort (80% of the patients) and found the same conclusion. This observation is important because in the large study by Calle et al., the inverse association between BMI and mortality seemed to have disappeared in female nonsmokers, 1 whereas in our study, BMI was independent of patients' sex and smoking history. Future study in nonsmoking patients is needed to understand this.
In summary, in this large, single-center retrospective series of patients with lung cancer, after control for disease stage and other variables, a BMI higher than 30 was associated with improved OS after surgical resection of NSCLC. Further studies are necessary to confirm these findings and to define the molecular or metabolic mechanisms linking BMI and treatment outcomes.
